In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

Secukinumab Drug Survival in Patients with Psoriasis: A multicenter, real-world, retrospective study

(2019) Tiago Torres et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: results from extension phase of the SUPREME study

(2019) M. Papini et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab dosing optimization in patients with moderate to severe plaque psoriasis: Results from the randomised, open‐label OPTIMISE study

(2019) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Real world data from the use of secukinumab in the treatment of moderate‐to‐severe psoriasis, including scalp and palmoplantar psoriasis: A 104‐week clinical study

(2019) Natalia Rompoti et al.   Dermatologic Therapy

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real‐life effectiveness and safety from the PROSPECT study

(2019) D. Thaçi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Anti IL-17 in psoriasis

(2019) Karen Ly et al.   Expert Review of Clinical Immunology

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

(2019) Andrea Chiricozzi et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study

(2018) A. Costanzo et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

(2018) Andreas Körber et al.   DRUGS & AGING

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

(2018) Marco Galluzzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study

(2018) L. Iversen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

(2018) R. Bissonnette et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain

(2018) Jaime Notario et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis

(2018) Nick Dand et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks

(2018) Esther von Stebut et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study

(2017) A. Körber et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study

(2017) J.R. Georgakopoulos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Current and Under Development Treatment Modalities of Psoriasis: A Review

(2017) Abdullah Albaghdadi   Endocrine Metabolic & Immune Disorders-Drug Targets

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

(2017) Jillian Frieder et al.   Therapeutic Advances in Chronic Disease

Secukinumab: First Global Approval

(2015) Mark Sanford et al.   DRUGS

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States

(2015) Caroline P. Schaefer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice

(2015) B. Polistena et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The emerging role of resident memory T cells in protective immunity and inflammatory disease

(2015) Chang Ook Park et al.   NATURE MEDICINE

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

(2014) G. Girolomoni et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of IL-17A blockade with secukinumab in autoimmune diseases

(2012) Dhavalkumar D Patel et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting IL-17 and TH17 cells in chronic inflammation

(2012) Pierre Miossec et al.   NATURE REVIEWS DRUG DISCOVERY

Gone but Not Forgotten: Lesional Memory in Psoriatic Skin

(2011) Rachael A. Clark   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY